Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534402 | 0.85 | MTNR1A (0.52) | MTNR1AMTNR1BNOTUMHTR2B | |
| SCHEMBL534744 | 0.81 | MTNR1A (0.51) | MTNR1AMTNR1BTSHRKMT2A | |
| SCHEMBL534971 | 0.78 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL17689405 | 0.76 | MTNR1A (0.59) | MTNR1AMTNR1BNOTUMHTR2B | |
| SCHEMBL15524127 | 0.76 | ICMT (0.39) | — | |
| SCHEMBL3075234 | 0.75 | MTNR1A (0.58) | MTNR1AMTNR1BNOTUM | |
| SCHEMBL31627780 | 0.74 | MTNR1A (0.57) | MTNR1AMTNR1BNOTUM | |
| SCHEMBL534533 | 0.74 | MTNR1A (0.57) | MTNR1AMTNR1BNOTUM | |
| SCHEMBL3074120 | 0.73 | MTNR1A (0.59) | MTNR1AMTNR1BNOTUMTSHRKMT2A | |
| SCHEMBL3621665 | 0.71 | ALDH1A1 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MTNR1A 2293/4885MTNR1B 1285/4885NOTUM 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.